OnKure Therapeutics, Inc. OKUR Business Segments — Indirect Program Expense

Similar metrics at other companies

BCRXOther non-program specific and indirect costs — Research and Development Expense (Excluding Acquired in Process Cost)

$7.42M+13.3%

LBR

LBRXClinical Trial — Direct Research And Development Expenses

$1.18M-88.8%

IMNMSingle Reportable — Indirect Research And Development Expense

-$16.31M-57.8%

GERNResearch and clinical expenses — R&D

$13M-5.1%

RNTXClinical Operation Activities — Research And Development Expense

$1.96M+191%

CAMPR&D — Clinical and preclinical expenses

$4.63M+3.4%

Questions, answered.

What is OnKure Therapeutics, Inc.'s business segments — indirect program expense?

OnKure Therapeutics, Inc. (OKUR) reported business segments — indirect program expense of $474K in Q1 2026.

How has OnKure Therapeutics, Inc.'s business segments — indirect program expense changed year-over-year?

OnKure Therapeutics, Inc.'s business segments — indirect program expense decreased by 9.9% year-over-year, from $526K to $474K.

What does business segments — indirect program expense mean?

Captures the overhead and supporting costs associated with clinical research operations that are not directly tied to a single specific clinical trial. These expenses typically include facility maintenance, administrative support for R&D departments, and general research infrastructure. It provides insight into the operational efficiency of the research organization beyond direct trial execution.